Luc BUEE PhD Neurobiology

Course and current status

Since 2020: Director, Lille Neuroscience & Cognition research centre (Inserm U1172), Lille, France

Since 2019: President, Société des Neurosciences

Since 2019: DRCE CNRS - Research professor

2017-2019: President-elect, Société des Neurosciences

2015-2019: Director, Jean-Pierre Aubert research centre, Lille, France

2010-2014: Deputy director, Jean-Pierre Aubert research centre (Inserm U837), Lille, France

2009-2019: DR1 CNRS - Research professor

Since 2006: Head of the Inserm team, Alzheimer & Tauopathies, Inserm U815 & U837

2001-2009: DR2 CNRS - Research professor

1997: Habilitation to conduct scientific research

1994-2001: Chargé de recherche au CNRS - CNRS Researcher, Inserm U156 & U422

Oct. 1992 PhD Neuroscience, The role of proteoglycans in Alzheimer amyloidosis. Univ. Lille, France

1989-1992: PhD student (Supervisors: Howard Fillit (US) & A Delacourte (French)), Dept Geriatrics (Robert N Butler), Mount Sinai Med Ctr, NYC, USA.

Scientific summary

Luc Buée is a French scientist (Directeur de Recherche au CNRS - DRCE CNRS), Director of the Lille Neuroscience & Cognition Research Centre and Head of the Inserm laboratory « Alzheimer & Tauopathies » at the University of Lille, France. Located on the Lille hospital campus, his laboratory belongs to the Lille Centre of Excellence in Neurodegenerative disorders (LiCEND) and is also part of the LabEx DISTALZ (National consortium on Alzheimer's disease).

Luc Buée has worked on Alzheimer's disease and related disorders for more than thirty years. He started his work on the role of proteoglycans in Alzheimer's disease with a PhD training at Mount Sinai Medical Center, NYC. He made some pioneering neuropathological observations on microvasculature abnormalities in neurodegenerative disorders. He was involved in the initial biochemical characterization of tau aggregates among neurodegenerative disorders (Tauopathies barcode). He has then developed experimental models to better understand the role of post-translational modifications in tau aggregation and tau secretion. Such experimental models are now widely used to evaluate therapeutic strategies in tauopathies (immunotherapy, small molecules, non-drug therapy...). With his team, he has also discovered many of the non-microtubular tau functions. He is currently working on the pathophysiological consequences of neurofibrillary degeneration and their links to the amyloid pathology and neuroinflammation in Alzheimer disease. His group was/is also involved in different international consortia.

Luc Buée is also involved in different scientific advisory boards and operating committees (National committee of Universities, Neuroscience section (CNU69), Janssen Horizon, Rainwater Charitable Foundation). He is also the representative researcher elected by academia colleagues at the French Foundation Plan Alzheimer. He is the organizer of the Eurotau meetings.
Since October 2019, he is the president of the French Society for Neuroscience (Société des Neurosciences).

Image d’exemple